Heartflow earnings release, May 14, 2026

Heartflow, Inc. (HTFL) · Form 8-K, Item 2.02 · Filed · SEC filing

Heartflow Reports

F irst

Quarter 202⁶

Financial Results and Raises Full Year 2026 Guidance

SAN FRANCISCO — Ma y¹⁴, 202⁶ – Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today reported financial results for the f irst quarter ended

March³¹, 202⁶.

F irst

Quarter 202⁶

Highlights

2026 Annual Guidance

“Heartflow entered 2026 with unprecedented momentum, expanding the category leadership we established over the last several years,” said John Farquhar, President and CEO of Heartflow. “Our AI-driven platform, deeply embedded commercial footprint, and the world’s largest database that recently expanded to over 200 million annotated CCTA images combine to create a foundational advantage that grows stronger with every quarter. The growth of our core FFRCT business remains durable, and adoption of Heartflow Plaque Analysis is ramping ahead of schedule. Most importantly, by helping physicians guide the care of over 650,000 patients worldwide, Heartflow has achieved an unrivaled scale of real-world experience. As the architects of this category, we continue to extend our lead ership position, becoming the

AI operating system of record for the detection, diagnosis, management, and treatment planning of coronary artery disease.”

F irst

Quarter 202⁶

Financial Results

Total revenue was $52.6 million, a 41% increase year-over-year. U.S. revenue was $48.3 million, a 42% increase year-over-year. International and other revenue was $4.3 million, a 34% increase year-over-year. The year-over-year increase in total global revenue was primarily attributable to an increase in total U.S. FFRCT volume.

Gross profit was $42.2 million, compared to $27.9 million in the prior year period. Non-GAAP gross profit was $42.3 million, compared to $28.0 million in the prior year period.

Gross margin was 80.2%, compared to 75.1% in the prior year period. Non-GAAP gross margin was 80.5%, compared to 75.3% in the prior year period. The year-over-year gross margin expansion was primarily attributable to an increase in revenue case volume and improved production team productivity driven by AI efficiency initiatives, partially offset by the hiring and training of production team personnel.

Total operating expenses were $71.7 million, or 136% of total revenue, compared to $45.4 million, or 122% of total revenue, in the prior year period.

GAAP o perating expenses also included a $7.5 million non-cash impairment charge related to the right-of-use asset for our Mountain View, California facility. The Company optimized its facilities footprint and relocated its headquarters to San Francisco.

Non-GAAP total operating expenses were $57.8 million, or 110% of total revenue, compared to $43.0 million, or 116% of total revenue, in the prior year period. The year-over-year operating expense increase was primarily attributable to increased investment in sales personnel and related expenses, as well as increased investments in technology and clinical research.

Net operating loss was $29.5 million, compared to $17.5 million in the prior year period. Non-GAAP net operating loss was $15.5 million, compared to $15.0 million in the prior year period.

Net loss was $27.4 million, or ($0.32) net loss per share, compared to $32.3 million, or ($5.25) net loss per share, in the prior year period. Non-GAAP net loss was $13.3 million, or ($0.16) non-GAAP net loss per share, compared to $19.2 million, or ($3.11) non-GAAP net loss per share, in the prior year period.

Adjusted EBITDA was ($14.0) million, compared to ($13.6) million in the prior year period.

Cash, cash equivalents and investments totaled $254.9 million as of March 31, 2026.

For additional information regarding non-GAAP financial measures, see “Use of Non-GAAP Measures,” “Heartflow GAAP to Non-GAAP Reconciliations” and “Reconciliation of GAAP Net Loss to Adjusted EBITDA” below.

Webcast and Conference Call Details

Heartflow will host a conference call today, Ma y¹⁴, 2026, at 1:30 p.m. PT / 4:30 p.m. ET to discuss its first quarter 202⁶ financial results. Those interested in listening to the conference call should register online using this link. Once registered, participants will receive dial-in numbers and a unique

PIN to join the call. Participants are encouraged to register more than 15 minutes prior to the start of the call. A live and archived webcast of the event will also be available on the “Investor Relations” section of the Heartflow website at https://ir.heartflow.com/. The archived version will be available for 12 months following completion of the live call.

About Heartflow’s Technology and Research

Heartflow’s technology is redefining precision cardiovascular care through clinically-proven AI and the world’s largest coronary imaging dataset. Heartflow has been adopted by more than 1,⁸

00 institutions globally and continues to strengthen its commercial presence to make this cutting-edge solution more widely available to an increasingly diverse patient population. Backed by American College of Cardiology and American Heart Association (ACC/AHA) guidelines and supported by more than 6²⁵ peer-reviewed publications, Heartflow has redefined how clinicians manage care for nearly⁶⁵

0,000 patients worldwide.¹

Key benefits include:

_________________________¹

Gulati, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation & Diagnosis of Chest Pain. J Am Coll Cardiol evidence to improve patient outcomes.

2,3,4,5... (truncated)TA image acceptance rates exceed 9⁷

%.

About Heartflow, Inc.

Heartflow is transforming coronary artery disease from the world’s leading cause of death into a condition that can be detected early, diagnosed accurately, and managed for life. The

Heartflow One platform uses AI to turn coronary CTA images into personalized 3D models of the heart, providing clinically meaningful, actionable insights into plaque location, volume, and composition and its effect on blood flow — all without invasive procedures. Discover how we’re shaping the future of cardiovascular care at heartflow.com.

Use of Non-GAAP Measures

To supplement its consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company discloses non-GAAP gross profit and non-GAAP gross margin, non-GAAP total operating expenses, non-GAAP research and development expense, non-GAAP selling, general and administrative expense, non-GAAP net operating loss, non-GAAP net loss, non-GAAP net loss per share, basic and diluted, and

A djusted EBITDA (collectively, the “Non-GAAP Measures”) in this press release. As used by the Company, these measures are adjusted to exclude stock-based compensation expense from the comparable GAAP financial measure and, in the case of non-GAAP total operating expenses, non-GAAP loss from operations, non-GAAP net loss and non-GAAP net loss per share, basic and diluted, and an asset impairment charge.

Non-GAAP net loss and non-GAAP net loss per share, basic and diluted, are also adjusted for change in fair value of common stock warrant liability, change in fair value of derivative liability, and asset impairment charge. In addition, Adjusted EBITDA is calculated by adding back to net loss or excluding, as appropriate, interest income and expense, provision for income taxes, and charges for depreciation and amortization and is further adjusted by adding back in or excluding, stock-based compensation and, as appropriate, other income and expense items that are not reflective of the Company’s underlying continuing operating performance. Reconciliations of the Non-GAAP Measures to their most directly comparable GAAP financial measures are provided in the financial statement tables included at the end of this press release, and investors are encouraged to review the reconciliations. The Company believes the presentation of the Non-GAAP Measures, when shown in conjunction with the corresponding GAAP measures, provides useful information to investors as it provides visibility to the Company’s underlying continuing operating performance from period to period by excluding the impact of stock-based compensation and certain other items that are not reflective of the Company’s ongoing operations. Because of the variety of equity awards used by companies, the varying methodologies for determining stock-based compensation expense, the subjective assumptions used in those determinations, and the volatility in valuations that can be driven by market conditions outside the Company’s control, we believe excluding stock-based compensation expense enhances the ability of management and investors to understand and assess the underlying performance of our business over time and compare it against our peers, a majority of whom also exclude stock-based compensation expense from their non-GAAP results. With respect to the presentation of Adjusted EBITDA, the Company believes it is a useful measure to evaluate the Company’s operating performance and it is used by the Company to evaluate ongoing operations and for planning and forecasting purposes. Adjusted EBITDA is also

_________________________²

Narula, et al. E HJ CVI 2024³

Danad, et al. JAMA Cardiol 2017⁴

Fairbairn et al. Coronary CT Angiography Plaque as a Predictor of Death, Cardiovascular Death and Myocardial Infarction. Presented at AHA 2025. (Real-world study with n=7,899 patients, higher TPV results in increased cardiovascular death and MI)⁵

Madsen KT, et al. ADVANCE-DK 7-year. Presented at TCT Scientific Sessions 2024 (n=900 patients determined a 2.5x increase in cardiovascular events or deaths at 7 years) a measure frequently used by analysts, investors and other interested parties to evaluate companies in our same industry.

The Company’s definition of the Non-GAAP Measures may differ from similarly titled measures used by others. The Non-GAAP Measures should be considered only as a supplement to, and not as a substitute for, or superior to, their most directly comparable GAAP financial measures. Because the Non-GAAP Measures exclude the effect of items that increase or decrease the Company’s reported results of operations, management strongly encourages investors to review the reconciliations to the most comparable GAAP financial measures at the end of this press release and, when they become available, the Company’s consolidated financial statements and publicly filed Securities and Exchange Commission (“SEC”) reports in their entirety.

The Company is not able to provide a reconciliation without unreasonable efforts of its forward-looking guidance related to non-GAAP gross margin to the most directly comparable GAAP financial measure due to the unknown effect of stock-based compensation that is material to the comparable GAAP financial measure.

Financial statements

Income Statement

Three Months Ended — 

Three Months Ended – March 31, – 2026Three Months Ended – March 31, – 2025
Revenue52,58737,205
Cost of revenue10,4239,264
Gross profit42,16427,941
Operating Expenses:Research and development21,62013,924
Operating Expenses:Selling, general and administrative42,56631,519
Operating Expenses:Asset impairment charge7,482
Operating Expenses:Total operating expenses71,66845,443
Operating Expenses:Loss from operations-29,504-17,502
Operating Expenses:Interest income2,464543
Operating Expenses:Interest expense-3-5,093
Operating Expenses:Change in fair value of common stock warrant liability-1,606
Operating Expenses:Change in fair value of derivative liability-9,045
Operating Expenses:Other income (expense), net-314358
Operating Expenses:Loss before provision for income taxes-27,357-32,345
Operating Expenses:Provision for income taxes-23
Operating Expenses:Net loss-27,380-32,345
Comprehensive loss:Net loss-27,380-32,345
Other comprehensive loss:Foreign currency translation gain (loss)262-236
Other comprehensive loss:Unrealized loss on investments, net-522
Other comprehensive loss:Total other comprehensive loss-260-236
Other comprehensive loss:Total comprehensive loss-27,640-32,581
Net loss per share, basic and diluted-0.32-5.25
Weighted-average shares used to compute net loss per share, basic and diluted85,639,6756,164,617

Income Statement

Three Months Ended March 31, 2026 — 

Three Months Ended March 31, 2026 – GAAPThree Months Ended March 31, 2026 – AdjustmentsThree Months Ended March 31, 2026 – Non-GAAPThree Months Ended March 31, 2025 – GAAPThree Months Ended March 31, 2025 – AdjustmentsThree Months Ended March 31, 2025 – Non-GAAP
Gross profit42,16416642,33027,9415727,998
Gross margin80.2%0.3%80.5%75.1%0.2%75.3%
Operating Expenses:Research and development21,620-2,13719,48313,924-54713,377
Operating Expenses:Selling, general and administrative42,566-4,25138,31531,519-1,88829,631
Operating Expenses:Asset impairment charge7,482-7,482$-$-$-$-
Operating Expenses:Total operating expenses71,668-13,87057,79845,443-2,43543,008
Loss from operations-29,50414,036-15,468-17,5022,492-15,010
Net loss-27,38014,036-13,344-32,34513,143-19,202
Net loss per share, basic and diluted-0.320.16-0.16-5.252.14-3.11

Income Statement

Three Months Ended — )

Three Months Ended – March 31, – 2026Three Months Ended – March 31, – 2025
GAAP net loss-27,380-32,345
Non-GAAP adjustments:Interest (income) expense, net-2,4614,550
Non-GAAP adjustments:Asset impairment charge7,482
Non-GAAP adjustments:Change in fair value of common stock warrant liability1,606
Non-GAAP adjustments:Change in fair value of derivative liability9,045
Non-GAAP adjustments:Other (income) expense, net314-358
Non-GAAP adjustments:Provision for income taxes23
Non-GAAP adjustments:Depreciation and amortization1,4231,372
Non-GAAP adjustments:Stock-based compensation expense6,5542,492
Non-GAAP adjustments:Adjusted EBITDA-14,045-13,638

Balance Sheet

December 31, — 

March 31, – 2026December 31, – 2025
Current assetsCash and cash equivalents19,67144,776
Current assetsShort-term investments138,645132,010
Current assetsAccounts receivable, net35,52729,343
Current assetsPrepaid expenses and other current assets17,98714,075
Current assetsTotal current assets211,830220,204
Current assetsLong-term investments96,582103,365
Current assetsProperty and equipment, net9,8298,587
Current assetsOperating lease right-of-use assets14,40717,488
Current assetsRestricted cash, non-current4,7024,709
Current assetsOther non-current assets6,6755,099
Current assetsTotal assets344,025359,452
Current liabilitiesAccounts payable5,7503,169
Current liabilitiesAccrued expenses and other current liabilities25,88633,279
Current liabilitiesOperating lease liabilities, current portion6,3825,922
Current liabilitiesTotal current liabilities38,01842,370
Current liabilitiesOperating lease liabilities, non-current portion19,96716,132
Current liabilitiesOther non-current liabilities322303
Current liabilitiesTotal liabilities58,30758,805
Stockholders’ equityCommon stock, $0.001 par value8685
Stockholders’ equityAdditional paid-in capital1,401,4471,388,737
Stockholders’ equityAccumulated other comprehensive loss-685-425
Stockholders’ equityAccumulated deficit-1,115,130-1,087,750
Stockholders’ equityTotal stockholders’ equity285,718300,647
Stockholders’ equityTotal liabilities and stockholders’ equity344,025359,452
Full release

Forward-Looking Statements... (truncated)ts are based on management’s current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements, including, but not limited to: we may not be able to achieve or sustain profitability; our dependence on the success of our one product, Heartflow FFRCT Analysis; healthcare providers may be unwilling to change their standard practice regarding the evaluation of coronary artery disease; adoption of the Heartflow Platform by healthcare providers may be negatively impacted if third-party payors, including government payors, do not cover or provide adequate reimbursement; the concentration of our customer base; the significant competition we face in an environment of rapid technological change; the commercialization of Heartflow Plaque Analysis is nascent; risks associated with our use and development of AI models; risks related to failing to properly manage our future growth; disruption by catastrophic events; risks associated with our dependence on our information technology systems; security breaches that we cannot anticipate or successfully defend; extensive regulatory requirements we face to bring our products to market; and third parties could develop and commercial ize technology and products similar or identical to ours. For a more extensive description of these and other risks and uncertainties that could materially affect our results, you should read our filings with the SEC, including our

Annual Report on Form 10-K and

Quarterly Reports on Form 10-Q, as such filings may be amended, supplemented or superseded from time to time by other reports Heartflow files with the SEC. You should not place undue reliance on the forward-looking statements in this press release, which speak only as of the date hereof, and we undertake no obligation to update the forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

Investor Contact

Nick Laudico nlaudico@heartflow.com

Media Contact

Elliot Levy elevy@heartflow.com

Heartflow, Inc.

Consolidated Statements of Operations

(unaudited, in thousands, except share and per share data)

Heartflow, Inc.

Consolidated Balance Sheets

(unaudited, in thousands)

Heartflow, Inc.

GAAP to Non-GAAP Reconciliations

(unaudited, in thousands except per share amounts and percentage data)

( a)

Represents adjustments related to stock-based compensation expense

(b)

Represents adjustments for: (i) stock-based compensation expense of $⁶.⁵ million; and

(ii) asset impairment charge of

$7.⁵ million

(c)

Represents adjustments for: (i) stock-based compensation expense of $2.⁵ million; (ii) change in fair value of common stock warrant liability of $¹.⁶ million; and (iii) change in fair value of derivative liability of $9.0 million

Heartflow, Inc.

Reconciliation of GAAP Net Loss to

Adjusted EBITDA

(unaudited, in thousands)

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Heartflow earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.